G protein-coupled receptor (GPCR)
CRE Reporter Cell Lines
Signosis GPCR Luciferase Reporter Cell Lines: Pioneering Incretin & Metabolic Research
Obesity and diabetes are no longer just metabolic disorders—they are tightly linked to cardiovascular disease, cognitive decline, and increased risk of dementia, including Alzheimer’s disease. Incretin-based therapies such as GLP‑1 receptor (GLP‑1R) agonists have already transformed obesity and Type 2 diabetes (T2D) treatment, and emerging clinical and preclinical data now highlight their potential to protect the brain, preserve memory, and slow neurodegeneration.
To support this new wave of metabolic–neuro therapeutics, Signosis has developed a high-sensitivity platform of GPCR/CRE Luciferase Reporter Cell Lines targeting three key incretin-related receptors: GLP‑1R, GIPR, and amylin3 receptors. These engineered cell models enable precise, quantitative monitoring of receptor-driven cAMP/CRE signaling and are ideal for:
-
Obesity and T2D drug discovery:
Single-target validation of GLP‑1R, GIPR, and amylin agonists, as well as dual and multi-agonist “twincretin” and “tri-agonist” candidates designed to deliver superior weight loss, glycemic control, and cardiometabolic benefits. -
Neuroprotection and memory-focused research:
Evaluation of GLP‑1–based and mixed incretin agonists that show neuroprotective and memory-preserving effects in preclinical models and early clinical studies—such as liraglutide, a long-acting GLP‑1 analog reported to reduce brain atrophy and slow cognitive decline in Alzheimer’s disease. Using these reporter lines, researchers can directly demonstrate CRE activation by clinically relevant incretin analogs and candidate dual agonists with potential cognitive benefits. -
Next-generation small-molecule and oral incretin modulators:
High-throughput screening and characterization of oral GLP‑1R agonists, GIPR co-agonists, and non-peptide amylin modulators, using robust dose–response assays and pharmacological profiling in a unified, assay-ready format.
Together, the GLP‑1R, GIPR, and amylin3 CRE Reporter Cell Lines provide a unified platform that connects metabolic efficacy (weight, glucose, liver) with neurocognitive outcomes (learning, memory, neuroprotection)—enabling pharma and biotech teams to design, compare, and optimize the next generation of incretin-based therapies for obesity, diabetes, and neurodegenerative diseases.
Beyond our standard single-receptor cell lines, Signosis also develops customized dual-receptor reporter models, giving researchers the ability to study receptor crosstalk, synergistic effects, and novel therapeutic mechanisms—key areas for next-generation obesity and diabetes research.
Principle: Transforming Cellular Signaling into Quantifiable Light
Signosis GPCR Reporter Stable Cell Lines utilize a transcriptional reporter system to provide real-time, functional readouts of G protein-coupled receptor activation. Unlike binding assays that only show attachment, our system confirms biological activity.
The Signaling Cascade
The mechanism is built on the G protein-coupled receptor (GPCR) pathway, which is the primary driver for metabolic receptors like GLP-1R and GIPR:
-
Ligand Binding: An agonist (peptide or small molecule) binds to the receptor (e.g., GLP-1R, GIPR, or the CTR-RAMP3 complex).
-
Pathway Activation: This triggers the G protein-coupled receptor, stimulating Adenylyl Cyclase to increase intracellular cAMP levels.
-
Transcription Induction: Elevated cAMP activates Protein Kinase A (PKA), leading to the phosphorylation of CREB.
-
Luciferase Expression: Phospho-CREB binds to the cAMP Response Element (CRE) in the promoter, driving the expression of the Firefly Luciferase gene.
-
Quantitative Readout: The resulting luminescence is directly proportional to the receptor's activation state, offering a high signal-to-noise ratio and a wide dynamic range.
Validation & Reliability
-
Diverse Ligand Compatibility: Functionally validated with both high-molecular-weight peptides and synthetic small molecules.
-
Stability: Established through rigorous antibiotic selection to ensure consistent performance over 25+ passages.
-
Pharmacological Precision: Ideal for determining EC50 and IC50 values in competitive inhibition or activation studies.
Ligand binding to GLP1R, GIPR, or the CTR-RAMP3 complex activates Gs-coupled signaling, leading to increased cAMP, PKA activation, and CRE phosphorylation. Phospho-CREB drives transcription of a CRE-luciferase reporter, producing light via firefly luciferase.
Metabolic & Incretin Reporter Lines
GLP-1R Reporter Cell Lines
GIPR Reporter Cell Lines
Name | SKU | Price (USD) |
|---|---|---|
GIPR/CRE Luciferase Reporter HEK293 Stable Cell Line | SL-6002 | $3,870.00 |
GIPR (E354Q)/CRE Luciferase Reporter HEK293 Stable Cell Line SL-6002-2 | SL-6002-2 | $3,870.00 |
Amylin3 Reporter Cell Lines
Name | SKU | Price (USD) |
|---|---|---|
Amylin3/CRE Luciferase Reporter HEK293 Stable Cell Line (2 vials) | SL-6003 | $3,870.00 |
Benefits
High Induction
Over 100x Induction delivers clear, measurable responses for confident data interpretation.
Mycoplasma free
Rigorously screened to ensure clean, contamination-free cultures for reliable results.
Ligand-Responsive Readout
Uses the cAMP luciferase system to give a strong, measurable signal only when a ligand activates the receptor.
Mechanism-Focused Research
Helps researchers better understand how specific GIPR isoforms function in different pathways or diseases.
Ready to Use
Stable Cell Lines are immediately ready to use — no extra transfections or optimization needed.
Isoform-Specific Detection
Designed to measure the activity of GPCR, avoiding cross-reactivity seen in traditional assays.
Stable and Reproducible
Stably integrated reporter constructs ensure reproducible performance without the need for repeated transfections.
Fully Validated Performance
Each cell line is tested for correct receptor expression, ligand response, and antibiotic selection.
Fast and Easy Compound Screening
Compatible with both high-throughput and common assay formats, making them ideal for testing drugs or compounds that target GPCR receptors.
Improved Accuracy
Focuses on the receptor’s ligand-binding domain (LBD) instead of the shared DNA-binding region for more precise results.
Broad Agonist Responsiveness
The cell line is functionally validated to respond to both peptide and non-peptide agonists.
We offer a highly sensitive Firefly Luciferase Substrate, which can accurately measure firefly luciferase activity in cells.
Customer Q&As
Q: What GPCR pathways do these reporter cell lines detect?
A: These cell lines primarily monitor GPCR-mediated cAMP/CRE signaling using a luciferase reporter system.
Q: Are these GPCR reporter cell lines suitable for high-throughput screening?
A: Yes. These cell lines generate a robust luminescent signal with low background and are fully compatible with 96-, 384-, and 1536-well HTS formats, making them ideal for drug discovery and screening applications.
Q: Can you customize GPCR reporter cell lines?
A: Yes, Signosis offers custom GPCR reporter cell line development upon request.
Q: What cell background is used for GPCR reporter cell lines?
A: Most GPCR luciferase reporter cell lines are generated in HEK293 cells, providing high transfection efficiency, robust growth, and consistent assay performance.
Q: Can these cell lines be used for agonist and antagonist screening?
A: Yes. GPCR luciferase reporter cell lines are commonly used to evaluate agonist activity, antagonist inhibition, and dose-response relationships (EC50/IC50).
Q: Can these cell lines be used for compound profiling and SAR studies?
A: Yes. These cell lines are well suited for compound profiling, structure–activity relationship (SAR) studies, and lead optimization.
